| Foot Pain Center Of Kansas City | |
|
230-c East Main St., Gardner, KS 66030-1643 | |
| (913) 856-8150 | |
| (913) 856-8390 |
| Full Name | Foot Pain Center Of Kansas City |
|---|---|
| Type | Facility |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 230-c East Main St., Gardner, Kansas |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689967119 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | 1200358KS (Kansas) | Secondary |
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 12-00358KS (Kansas) | Primary |
| Provider Name | Jacob Goldstein |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1003896374 PECOS PAC ID: 8325011539 Enrollment ID: I20061016000490 |
News Archive
Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control.
In a presentation at the annual meeting of the Heart Failure Association of the European Society of Cardiology, and in a simultaneous publication in Circulation, investigators from Brigham and Women's Hospital presented evidence that a next-generation cardiac pump device not only improves long-term outcomes but may also decrease cost of care over time for heart failure patients.
Anti-caking agents in powdered products may hasten degradation of vitamin C instead of doing what they are supposed to do: protect the nutrient from moisture.
A team of investigators has discovered that the underexpression of a specific metabolic enzyme is a common and adverse epigenetic modulating feature in clear cell renal cell carcinoma (ccRCC), according to a recent study published in Proceedings of the National Academy of Sciences.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Foot Pain Center Of Kansas City 230-c East Main Street, Gardner, KS 66030-1643 Ph: (913) 856-8150 | Foot Pain Center Of Kansas City 230-c East Main St., Gardner, KS 66030-1643 Ph: (913) 856-8150 |
News Archive
Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control.
In a presentation at the annual meeting of the Heart Failure Association of the European Society of Cardiology, and in a simultaneous publication in Circulation, investigators from Brigham and Women's Hospital presented evidence that a next-generation cardiac pump device not only improves long-term outcomes but may also decrease cost of care over time for heart failure patients.
Anti-caking agents in powdered products may hasten degradation of vitamin C instead of doing what they are supposed to do: protect the nutrient from moisture.
A team of investigators has discovered that the underexpression of a specific metabolic enzyme is a common and adverse epigenetic modulating feature in clear cell renal cell carcinoma (ccRCC), according to a recent study published in Proceedings of the National Academy of Sciences.
› Verified 5 days ago
Dr. Jacob B. Goldstein, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 230-c East Main St., Gardner, KS 66030 Phone: 913-856-8150 Fax: 913-856-8390 |